Moxifloxacin aqueous formulation for parenteral introduction |
|||||||||||||||||||||||||||||||||
|
IPC classes for russian patent Moxifloxacin aqueous formulation for parenteral introduction (RU 2472507):
 3-amino-6-(1-aminoethyl)tetrahydropyrane derivatives / 2471795
Invention refers to new antibacterial compounds of formula I
 Mutant antigens gas57 and gas57 antibodies / 2471497
Group of invention refers to medicine, particularly to producing a mutant antigen GAS57 containing an amino acid modification in two or more positions of amino acids specified in a group consisting of consisting of amino acids D151, H279 and S617 wherein said positions of amino acids are numbered according to SEQ ID N0:1 which is not able to split IL-8 and analogous substrates with keeping an ability to provide protection of the infections caused by S. pyogenes. The group of inventions also comprises a nucleic acid molecule coding a purified mutant antigen GAS57, a method for producing a mutant antigen, a composition and a method for producing it, a method for treating or preventing an infectious disease caused by S. pyogenes. Said mutants may be used inter alia in vaccine compositions.
Method for preparing composition for injections containing sodium cevtriaxone and sodium tazobactam / 2471484
Method for preparing a composition for injections containing sodium cevtriaxone and sodium tazobactam involves the following stages: (a) suspension of raw materials, i.e. sodium cevtriaxone, sodium tazobactam, sterilised water for injections, mixed solution of ethyl acetate and isopropyl alcohol, and anhydrous ethanol in mass relation making 3-5:1:2:5:9, with volume relation of ethyl acetate to isopropyl alcohol making 1:2-4; (b) dissolution of sodium cevtriaxone and sodium tazobactam in sterilised water for injections with added activated hydrocarbon and filtration; (c) addition of the mixed solution of ethyl acetate and isopropyl alcohol to the filtrate and agitation of the mixture; addition of a seed crystal of sodium cevtriaxone to the solution for crystallisation initiation; and finally washing of the crystals in anhydrous ethanol and crystal drying; and (d) lyophilisation to form the composition for injections containing sodium cevtriaxone and sodium tazobactam.
 Complex composition of chitosan succinate and chlorhexidine possessing antibacterial and wound healing effect / 2471477
Invention refers to medicine. What is described is a complex of chitosan and dioxydine with chlorhexidine at mass ratio of chitosan succinate with dioxidine 4.25-6:1 and chlorhexidine 60-85.0:1 respectively.
Method for integrated treatment of maxillofacial abscesses and phlegmons in children by ointment with furacilin, lidocaine and dibunol / 2470629
Offered invention refers to medicine, namely dentistry, and may be used for treating children suffering maxillofacial abscesses and phlegmons. That is ensured by opening of a suppurative focus, wound bathing and drainage. With underlying conventional antibacterial therapy, an ointment containing furacilin, lidocaine and dibunol as active agents and a styrene maleic anhydride copolymer, Lutrol F-127 and purified water in certain proportions as an ointment base is introduced in the suppurative cavity. Furacilin - 0.2, Lidocaine - 5.0, Dibunol - 5.0, Styrene maleic anhydride copolymer - 2.0, Lutrol F-127 2.0 and Purified water to 100.0.
Composition for treatment or prevention of gastrointestinal infection / 2469735
Composition for treatment and/or prevention of infection with gastrointestinal pathogens and/or disease of mammals, associated with infection by said pathogens, contains lipid, protein and hydrocarbon part, where lipid part provides from 5 to 50% of total number of calories, protein part provides from 5 to 50% of total number of calories and carbohydrate part provided from 15 to 90% of total number of calories. Protein part contains: (i) pea protein hydrolysate and (ii) at least one source of nitrogen, selected from the group, consisting of milk proteins, milk protein hydrolysate, egg protein and egg protein hydrolysate.
 3-(2-bromophenyl) and 3-benzyl-4,5,6,7-tetrahydroindazole hydrochlorides, antimicrobial agent based thereon / 2469027
Present invention relates to organic chemistry and specifically to novel biologically active indazole compounds: 3-(2-bromophenyl)-4,5,6,7-tetrahydroindazole hydrochloride (1a) and 3-benzyl-4,5,6,7-tetrahydroindazole hydrochloride (1b) of general formula:
 Sorption, antimicrobial and deodorising medication for external application / 2468795
Invention relates to chemical-pharmaceutical industry, in particular, to production of drugs for external application. As shaping component used is sterile hydrophilic powder of Kimmeridgian (blue) medicinal "Undorovskaya" powder-like, as deodorating -menthol powder, and as solvent and penetrator - dimethylsulphoxide with the following ratio of components (wt %): menthol 1.5-3.5, furacillin 1.0-5.0, dimethylsulphoxide 20.0-24.0, blue clay 74.0-67.0.
Method of obtaining staphylococcal anatoxin-vaccine / 2468078
Invention relates to obtaining and application of staphylococcal anatoxin-vaccine for prevention and treatment of animal diseases of staphylococcal etiology. Method by invention includes growing staphylococci on synthetic nutritional medium with further autoclaving of obtained suspension of microorganisms. After that, detoxication of obtained complex of staphylococcal exo-, endo- and superenterotoxins is performed by two detoxicators: first by 0.2-0.3% glutardehyde solution during 3-5 days at 40-42°C, then by 0.2% ethonium solution or 0.15-0.25% solution of alkylmethylbenzyl ammonium during 3-5 days at 40-42°C. After that, target product is sorbed on aluminium hydroxide in dose 3-5 mg/ml.
 Antibacterial peptides / 2468033
Present invention relates to peptides having antibacterial and endotoxin-neutralising activity, having general formula (Xaa1)M-(Xaa2)o-Xaa3-(Xaa4)p-(Xaa5)Q-(Xaa6)M-(Xaa7)R-(Xaa8)S.
Method for preparing composition for injections containing sodium cevtriaxone and sodium tazobactam / 2471484
Method for preparing a composition for injections containing sodium cevtriaxone and sodium tazobactam involves the following stages: (a) suspension of raw materials, i.e. sodium cevtriaxone, sodium tazobactam, sterilised water for injections, mixed solution of ethyl acetate and isopropyl alcohol, and anhydrous ethanol in mass relation making 3-5:1:2:5:9, with volume relation of ethyl acetate to isopropyl alcohol making 1:2-4; (b) dissolution of sodium cevtriaxone and sodium tazobactam in sterilised water for injections with added activated hydrocarbon and filtration; (c) addition of the mixed solution of ethyl acetate and isopropyl alcohol to the filtrate and agitation of the mixture; addition of a seed crystal of sodium cevtriaxone to the solution for crystallisation initiation; and finally washing of the crystals in anhydrous ethanol and crystal drying; and (d) lyophilisation to form the composition for injections containing sodium cevtriaxone and sodium tazobactam.
Pharmaceutical composition for treating alcoholism, drug addiction and chemical abuse with improved naltrexone release profile / 2471478
Invention refers to medicine and pharmacy, namely addictology and may be used for treating human addiction to alcohol, drugs and toxic substances. An intramuscularly injected prolonged-release pharmaceutical composition contains naltrexone as an active substance. Additionally, the composition contains a pharmaceutically acceptable solvent and excipients differing by the fact that the active substance is included in first and second microsphere fractions of polylactide coglycolide. The first microsphere fraction is characterized by the relation of lactide and glycolide monomer links 50 mole %:50 mole % and microsphere size 0.4 to 7 mcm. The second microsphere fraction is characterized by the relation of lactide and glycolide monomer links 75 mole %:25 mole % and microsphere size 20 to 90 mcm. A weight ratio of the first fraction of 0.01 to 0.15, while a weight ratio of the second fraction is 0.99 to 0.85.
 Method for ecological, explosion and fire proof technological production of injection forms of antidote amylnitrite / 2470633
Invention refers to chemical technology and represents a method for producing injection forms of the preparation 'amylnitrite' in the form of ampoules characterised by the fact that: cooled ampoules are supplied; a container of the diametre of max. 30 mm cooled by dry ice and containing amylnitrite in the amount of max.100 g is mounted; transport system hoses of the internal diametre of 2.5-3 mm are connected through a sampling needle; amylnitrite is filled out with a flexible-hose pump; the ampoules are sealed with the use of the distant introduction of filling-out and sealing; provided: the procedure performed in workplaces of range of purity 'B' and higher in the presence of local extraction ventilation available to provide min. 10 air chambers per hour, equipped with BAU-a grade absorbent chemical filter; the amylnitrite vapour concentration is maintained in the workplace and in vent air at a level not exceeding the maximum allowable of amylnitrite in 1 mg/m.
 Liquid formulations / 2470631
Present invention refers to medicine and describes a pharmaceutical concentration for dissolution before oral introduction, containing S1P receptor modulator or agonist specified in a group involving 2-amino-2-[2-(4-octylphenylethyl)]propane-1,3-diol, 2-amino-2-[4-(benzyloxyphenylthio)-2-chlorophenyl]ethyl-1,3-propanediol or proper phosphate, and 1-{4-[1-(4-cyclohexyl-3-trifluoromethylbenzyloxyimino)ethyl]-2-ethylbenzyl}azetidine-3-carboxylic acid, or their pharmaceutically acceptable salts, respectively, and 65 to 99 wt % propylene glycol, and optionally one or more other solvents, one or more aromatisers and/or one or more preserving agents; all the ingredients are added up to 100 wt %. What is also described is a pharmaceutical solution containing the concentrate, the use of the concentrate and the method for treating an individual in need of immune system suppression with the use of said concentrate.
Method of treating inflammatory eye diseases in human and animals for stimulation of repair processes and epithelisation / 2470630
Invention refers to chemical-pharmaceutical industry and medicine, ophthalmology, and may be used for treating corneal diseases and damages. Eye drops contain peptides associated with phospholipids, produced of cod liver, a lubricant, a buffer, a preserving agent, isotonic sodium chloride and water for injections under certain proportions. Eye drops may additionally contain an antioxidant in the amount of 0.01-0.5 wt % specified in a group consisting of sodium metabisulphite, sodium sulphite, sodium thiosulphate or trilon B provided the peptides associated with phospholipids are used in the relation of peptide and phospholipid fractions, wt %: 40-99 peptides and 1-60 phospholipids.
Medication for treating accommodation disorders "stiak" / 2469734
Method of treating accommodation disorders, including introduction of morning and evening compositions into conjunctival sac, with morning composition containing cytidine or digoxin, taufon or taurine, polyvinylpyrrolidone, menthol and rose water, and evening composition containing tropicamide, mezaton, digoxin or adenosine triphosphate, menthol and rose water and carrying out additionally aromatherapy with application of morning and evening compositions of essential oils, with morning composition containing essential oils of rosemary, lemon and geranium, and evening composition containing essential oils of bergamot, jasmine and orange, with specified component ratio.
 Corticosteroid-based composition with controlled release for treatment of ear diseases / 2469726
Pharmaceutical composition, suitable for application in treatment of ear diseases includes acceptable for ear thermoreversable water gel. Pharmaceutical composition consists of anti-inflammatory corticosteroid in form of multiple particles and polyoxypropylene and polyoxyethylene-based polymer. Composition is introduced locally to the subject, suffering from ear disease, by intratympanic introduction on membrane of cochlea window or near it.
Bischofite dosage form for treating pyoinflammatory processes of mucosae and skin / 2469705
Bischofite dosage form additionally contains ammonium salt of glycyrrhizic acid in the following proportions, wt %: standardised bischofite solution - 5-10; ammonium salt of glycyrrhizic acid - 0.1.
 Pharmaceutical composition for topic application / 2468794
Invention relates to medicine and pharmaceutical industry, namely, to composition for topic application of diclofenac. Composition includes diclofenac in acidic form in system of carriers, which includes multi-base alcohol, glycol ether and higher fatty acid ester, at usual temperatures said system of carriers represent one phase.
 Liquid compositions of phenylephrine with increased stability / 2468787
Invention relates to medicine and deals with liquid pharmaceutical composition for peroral application, containing phenylephrine or its pharmaceutically acceptable salt and in fact non-containing polyethylene glycol aldehides.
Method of treating depressive neurosis / 2465895
Invention relates to medicine, namely to psychiatry, and can be used in treatment of patients with depressive neurosis. For this purpose complex treatment, which includes, which includes introduction of medications and hyperbaric oxygenation, is performed. As medications introduced are paroxetin in dose 20-25 mg internally 1 time per day during 20 days, diazepam in dose 10-12 mg intramuscularly 2 times per day during 20 days, mexidol in daily dose 200-225 mg intravenously by drop infusion during first 10 days, and after that in dose 200-225 mg internally in tablets during the following 10 days, thymogen 0.01% solution in dose 1.2-1.3 ml intramuscularly 1 time per 2 days, 10 injections. Simultaneously with pharmacotherapy during first 10 days of treatment performed is hyperbaric oxygenation with excessive pressure 0.8-1.0 atmosphere with rate of compression and decompression 0.1 atmosphere per minute, with isopression period 40 minutes, 1 time per day.
|
FIELD: medicine, pharmaceutics. SUBSTANCE: present invention refers to chemical-pharmaceutical industry and presents a moxifloxacin aqueous formulation for parenteral introduction containing an active substance: moxifloxacin hydrochloride, water for injections and other ingredients used for parenteral introduction differing by the fact that said ingredients are presented by sodium ascorbate and sodium metabisulphite in the following proportions, g/l: moxifloxacin hydrochloride 15-25; sodium ascorbate 0.05-1; sodium metabisulphite 0.1-2; water for injections up to 1 l. EFFECT: invention provides creating a therapeutic agent providing a high therapeutic effect in prevention and treatment of bacterial infections by reduction of infectious and inflammatory processes in tissues, and reduced length of recovery. 2 ex
The invention relates to medicine, in particular to pharmacology, and relates to the creation of medicines on the basis of high concentration of the active substance moxifloxacin by parenteral administration for the prevention and treatment of bacterial infections in humans or animals. Moxifloxacin is a highly effective anti-infective agent (EP-A-0350733), including the active ingredient, microcrystalline cellulose, corn starch, poly(1-vinyl)-2-pyrrolidone (insoluble), highly dispersed silicon dioxide and magnesium stearate. The closest in technical essence and the achieved result is an aqueous composition on the basis of moxifloxacin for parenteral administration containing from 0.04 to 0.4 m/o (counting on the amount of moxifloxacin), and from 0.4 to 0.9 (m/o) of sodium chloride and water the rest. As well as aqueous composition containing from 0.008 to 0.32% (m/o) (considering on the amount of moxifloxacin) moxifloxacin-hydrochloride; an aqueous composition containing from 0.1 to 0.2% (m/o) (considering on the amount of moxifloxacin) moxifloxacin-hydrochloride; an aqueous composition containing from 0.5 to 0.9% (m/o) (considering on the amount of moxifloxacin) sodium chloride; aqueous composition containing from 0.7 to 0.9% (m/o) (considering on the amount of moxifloxacin) of sodium chloride. The specified water composition is used as a drug when estva for the prevention or treatment of bacterial infections in humans and animals (EN 2260429 C9, A61K 31/4709, 2004). The present invention is the creation of medicines for parenteral administration higher than in the prototype, the concentration of the active substance moxifloxacin-hydrochloride, used as an antibacterial, bactericidal means higher than in the prototype, bioavailability and stability with qualitative and quantitative selection of ingredients, including auxiliary. The technical result is obtained when using the claimed invention, is expressed at high therapeutic effect in the prevention and treatment of a wide range of diseases by edema infectious and inflammatory processes in tissues and reduce recovery time in 2-3 times in comparison with the known means. The product has a high stability, well tolerated and does not cause allergies and other side effects during treatment. To achieve the technical result of water composition on the basis of moxifloxacin for parenteral administration containing active ingredient: moxifloxacin hydrochloride, water for injection and other components used in parenteral, characterized in that the quality of these components contains sodium ascorbate and naturematerials in the following ratio of components, g/l:
Spent an analysis of the prior art, including searching by the patent and scientific and technical information sources, and identify sources that contain information about the equivalents of the claimed medicinal product, has allowed to establish that the petitioners have not found a similar, characterized by signs, identical to all the essential features of the claimed medicinal product. Therefore, the claimed combination medicinal product meets the criterion of "novelty." For verification of the compliance of medicines prior art, the applicants conducted an additional search of the known solutions to identify signs that match the distinctive features of the prototype of the characteristics of the claimed invention. The search results showed that the claimed invention not apparent to the expert in the obvious way from the prior art, certain applicants not identified impact provided the essential features of the claimed combined medicines transformations to achieve a technical result. Therefore, the claimed invention meets the criterion of "inventive step". The criteria of the invention "industrial applicability" is confirmed by the fact that the proposed drug has a high therapeutic effect in the prevention and treatment of a wide range of diseases by edema infectious and inflammatory processes in tissues and reduce recovery time in 2-3 times in comparison with the known means and can be successfully used to treat various infectious diseases. The drug is characterized by a wide spectrum of action. In relation to bacterial cells exerts bactericidal action. Claimed, the drug is highly active against most gram-negative and gram-positive bacteria. Rapidly and completely absorbed when injected into the human or animal body. Its absolute bioavailability of 99%. The maximum concentration in the blood is detected in 0.5-1 hour. The half-life is approximately 12 hours. About 20% of a single dose (400 mg) is excreted unchanged in the urine, about 25% in feces. The medicinal product is a concentrate for solution for infusion, which before use is diluted with a suitable solvent is m, for example isotonic sodium chloride solution or 5% dextrose. Used with infectious-inflammatory diseases: diseases of the respiratory tract, ear, throat, skin, soft tissues, bones, joints, infectious-inflammatory diseases of organs of abdominal cavity and small pelvis, kidney infections and urinary tract infections, prostatitis, gonorrhea, tuberculosis of the lungs in humans and animals. The drug is used parenterally. The dosage is determined individually depending on the severity of the disease. Daily dose of 400-800 mg daily use 1 time per day. The duration of treatment is 7-10 days. When carrying out the prevention and treatment of a wide range of diseases is the reduction in inflammatory processes in tissues and, consequently, reduced recovery time in 2-3 times in comparison with the known means. Specific examples Example 1. To get offered drugs in the capacity of a pharmaceutical purposes put water and dissolved therein with stirring active substance moxifloxacin-hydrochloride. In the solution of active substance added excipients: sodium ascorbate, sodium metabisulfite and dissolve. The solution is filtered through a sterile filter (0.2 μm). Fill the vial up to 20 ml and awayt. The resulting solution is stable when stored up to 5 years, with retention of therapeutic properties. These components are taken in the following ratio, g/l water:
Example 2. Carried out analogously to example 1, except that the specified components are taken in the following ratio, g/l water:
Thus, qualitative and quantitative selection of ingredients offer anti-bacterial, germicidal means on the basis of moxifloxacin allowed to obtain stable storage composition with good bioavailability. In the command structure on the basis of moxifloxacin for parenteral administration, containing active ingredient: moxifloxacin hydrochloride, water for injection and other components used in parenteral, characterized in that the quality of these components it contains sodium ascorbate, and sodium metabisulfite in the following ratio of components, g/l:
|
||||||||||||||||||||||||||||||||